Alteration of methylation status has been recognized as a possible epigenetic mechanism of selection during tumorigenesis in pancreatic cancer. This type of cancer is characterized by poor prognosis partly due to resistance to conventional drug treatments. We have used microarray technology to investigate the changes in global gene expression observed after treatment of different pancreatic cancer cell lines with the methylase inhibitor 5-aza-2 0 -deoxycytidine (5-aza-CdR). We have observed that this agent is able to inhibit to various degrees the growth of three pancreatic cancer cell lines. In particular, this inhibition was associated with induction of interferon (IFN)-related genes, as observed in other tumour types. Thus, expression of STAT1 seems to play a key role in the cellular response to treatment with the cytosine analogue. Moreover, we found increased p21 WAF1 and gadd45A expression to be associated with the efficacy of the treatment; this induction may correlate with activation of the IFN signalling pathway. Expression of the p16
Introduction
Abnormal patterns of DNA methylation have been recognized as a frequent molecular change involved in the initiation and progression of human neoplasia (Jones and Buckley, 1990; Baylin et al., 1991; Costello et al., 2000) . The importance of these epigenetic alterations has been highlighted in recent studies where human cancers could be classified by their methylation profile, with a correlation between methylation of CpG dinucleotides and the progression of tumours to malignancy (Costello et al., 2000; Adorjan et al., 2002) . DNA methylation normally occurs at the cytosine residues within CpG dinucleotides as a result of DNA methyltransferase (DNA MTase) activity. DNA MTase recognizes methylated CpG sites in the parent strand and catalyses addition of a methyl group to the daughter strand (Leonhardt et al., 1992; Yoder and Bestor, 1996) . The presence in the eukaryotic genome of these CpG sites has been progressively reduced during evolution, with the exception of CpG islands (Antequera and Bird, 1993; Bird, 1993) . These are frequently contained in the promoter regions or in the exons of different genes and are usually unmethylated in normal cells (Bird et al., 1985; Cross and Bird, 1995; De Smet et al., 1999) . Hypermethylation of CpG islands is associated with delayed DNA replication, condensed chromatin and inhibition of transcription initiation (Antequera et al., 1990; Tazi and Bird, 1990; Baylin et al., 1998; Jones and Wolffe, 1999) , and it has been observed in oncogenic transformation (Antequera et al., 1990) , in cancer-derived cell lines (Rideout et al., 1994) and uncultured tumours (Baylin et al., 1998; Costello et al., 2000) .
There are several growth-regulatory genes that have been found to be silenced by hypermethylation in different tumour types, including, for example, RB1 (Sakai et al., 1991) , VHL (Herman et al., 1994) , cyclin kinase inhibitors (p15, p16) (Herman et al., 1995 (Herman et al., , 1996 Bender et al., 1998; Lubomierski et al., 2001) , estrogen receptors (Ottaviano et al., 1994) and MLH1 (Kane et al., 1997) .
Pancreatic ductal adenocarcinoma is a lethal disease and represents the fifth most common cause of cancer death in the United States and Europe (Pisani et al., 1999) . This is mainly because it is inoperable at the time of diagnosis and has a stinking resistance to conventional treatments. The molecular basis of this aggressive clinical behaviour is as yet incompletely elucidated.
Alterations in methylation status have been recognized as an epigenetic mechanism of selection during tumorigenesis in this type of cancer, and a correlation between methylation patterns of pancreatic adenocarcinomas and their clinico-pathological features has been suggested (Ueki et al., 2001) . In addition, the hypermethylation of multiple specific genes appears a possible way for the tumour to silence some key pathways (Ueki et al., 2000; Venkatasubbarao et al., 2001) . The reactivation of these key genes using a demethylating agent might sensitize tumours to the action of chemotherapy.
The methylase inhibitor 5-Aza-2 0 -deoxycytidine (5-aza-CdR) is a cytosine analogue that is incorporated into DNA during replication. It covalently binds DNA methyltransferase and inhibits its activity, leading to genome-wide demethylation (Creusot et al., 1982; Santi et al., 1984; Michalowsky and Jones, 1987) . Numerous studies have shown the ability of 5-aza-CdR to inhibit or suppress the growth of human tumours in vitro and in vivo (Yamada et al., 1996; Bender et al., 1998; Eggert et al., 2000; Suh et al., 2000; Karpf et al., 2001) , while clinical trials are currently assessing the effectiveness of 5-aza-CdR in the treatment of both haematological and solid tumours (for reviews, see Santini et al., 2001; Aparicio and Weber, 2002) .
In the present study, we analysed the gene expression profile of three pancreatic cancer cell lines showing differential growth inhibition to treatment with 5-azaCdR. The growth inhibition was associated with the induction of interferon (IFN)-related genes. Importantly, the genome-wide demethylation significantly increased the response of PaCa44 and CFPAC1 cells to treatment with IFN-g, gemcitabine and cisplatin. This suggests a possible application of 5-aza-CdR in pancreatic cancer therapy in combination with other drugs.
Results

Growth inhibition, cell cycle profile and apoptosis induced by 5-aza-CdR treatment
Treatment with 5-aza-CdR induced growth inhibition that was more marked and lasted longer in PaCa44 and CFPAC1 than in MiaPaCa2 cells (Figure 1 ). At the sixth day, when the total RNAs for the gene expression profile analysis were extracted, the percentage of cells for PaCa44 and CFPAC1 compared to the control were, respectively, 18 and 28%, while MiaPaCa2 was 57%.
The cell cycle analysis by propidium iodide staining showed a delay in the progression with an increased proportion of cells in S and G2-M phases particularly for PaCa44 and CFPAC1, while the effect on MiaPaCa2 was less marked (Table 1) .
The level of apoptotic cells measured at the sixth day after treatment, by detection of histone-associated DNA in the cytoplasmic fraction, revealed that the treatment PaCa44  3  9  56  35  59  33  8  6  1 3  4 4  4 3  7 2  2 3  5  CFPAC1  3  35  20  45  73  19  8  6  4 9  2 6  2 5  8 5  1 0  5  MiaPaCa2  3  60  27  13  76  14  10  6 6 3 2 6 1 0 7 7 1 5 8
The assay was carried out in triplicate for each cell line and time point and performed the third and sixth days after treatment with 5-AzaCdR
Growth delay of human pancreatic cancer cells E Missiaglia et al with 5-aza-CdR induced only modest levels of apoptosis. Application of Annexin V staining confirmed the low levels of apoptosis induced (data not shown). This suggests that the low number of cells observed in treated samples was mostly an effect of growth inhibition.
Methylation status and DNMTs expression
The content of 5-methylcytosine (5mC) in the genomic DNA of control and treated cells was semiquantitatively measured using the McrBC enzyme. Figure 2 shows that treatment with 5-aza-CdR was able to induce generalized demethylation in the genomic DNA of all the three cell lines. The expression status of the four main methyltransferase genes assayed by RT-PCR assay is shown in Figure 3a . DNMT1, which is the principal target of the cytosine analogues, showed a lower level of expression after treatment in PaCa44 and CFPAC1, while a small increase occurred in MiaPaCa2, confirming the data obtained by microarray analysis (Supplementary Table  1 ). The observed expression levels of DNMT1 may not be due to a direct effect of 5-aza-CdR, but could be explained by its tight regulation during the cell cycle, with lower levels in G1/G0 and peak levels in S phase . In fact, 5-aza-CdR affects the enzyme activity rather than its expression, which is also in agreement with our data when we observed a minor upregulation of DNMT1 ( Figure 3a ) associated with genomic DNA demethylation in the MiaPaCa2 cell line (Figure 4 ). Another interesting aspect is the presence of different splicing variants of DNMT3b in the cell lines analysed. In particular, MiaPaCa2 shows a higher level of expression of splice variant 3, which is either not expressed or expressed at only a very low level in the other two cell lines.
The global gene expression profile shows similarities between PaCa44 and CFPAC1 and a different pattern for MiaPaCa2
In order to identify similarities in the effect of 5-azaCdR treatment on gene expression profile among the cell lines, we first compared the profile of control and treated cells using the Spearman correlation method. The coefficients were calculated comparing the log ratios obtained from each control and treated cell line against their appropriate reference (see the experimental design in methods). The results revealed a high correlation between PaCa44 and CFPAC1 (r-value ¼ 0.66; Po0.0001), while neither of these showed such a high correlation with MiaPaca2 (r-value ¼ 0.32 and 0.36, respectively; Po0.0001)). In addition, the differences between these correlations were statistically significant (both Po0.001). The same result was obtained using Euclidian distance based on wide gene sets (5306 features), as visualized by the hierarchical clustering reported in Figure 4 . Cutting the dendrogram as Dendrogram obtained by hierarchical cluster analysis using a wide gene set (5306 features) of control and treated samples at the 6th day after treatment. The analysis was performed using the 'mva' package applying an agglomerative method, average linkage and Euclidian distance. The dendrogram is cut by a horizontal line to demonstrate that all the treated CFPAC1 and PaCa44 samples fall in the same cluster, while treated MiaPaCa2 samples are closest to the cluster of control samples Growth delay of human pancreatic cancer cells E Missiaglia et al illustrated shows that the 5-aza-CdR-treated PaCa44 and CFPAC1 samples fall in a common cluster, while the 5-aza-CdR-treated MiaPaCa2 replicates clearly fall in a different cluster closer to the untreated samples of all lines. These observations are in agreement with the effect of 5-aza-CdR treatment on the growth characteristics of these cell lines, which was similar between PaCa44 and CFPAC1 and less pronounced in MiaPaCa2. This suggests the possibility that the treatment may have activated or silenced pathways common to the former two cell lines and different from those affected in MiaPaca2.
Genes induced or repressed by 5-aza-CdR treatment in the cell lines
To select differentially expressed genes, we used the statistical package SAM, with stringency and conditions described in Materials and methods. This highlighted 555 up-and 590 downregulated features in PaCa44, 395 up-and 357 downregulated features in CFPAC1 and 118 up-and four downregulated features in MiaPaCa2.
Since both PaCa44 and CFPAC1 showed similar growth and gene expression patterns after treatment with 5-aza-CdR, it is possible that a common set of genes is involved in their more marked growth inhibition. In order to identify such a common set, the lists of differentially expressed features of PaCa44 and CFPAC1 were superimposed. This analysis identified 127 unique genes (175 clones) upregulated and 123 unique genes (162 clones) downregulated in both PaCa44 and CFPAC1 (for the full lists see Supplementary Tables 1 and 2) .
We then analysed the biological process terms associated with the differentially expressed genes using the FatiGO Data mining and MAPPFinder programs (see Gene ontology analysis in Materials and methods). The total number of upregulated genes that show biological process terms in GO database at the fifth level using FatiGO was 77 (out of 117 genes identified with Ensembl-ID), while the number of genes downregulated was 79 (out of 113 genes identified with Ensembl-ID). Extending the analysis with the MAPPFinder program to higher-level nodes brought the figure to 112 and 106 genes, respectively, up-or downregulated and linked to a GO term.
In the upregulated data set, the only gene ontology term statistically significant at the adjusted level with FatiGO was 'defence response' (adjusted Po0.05), which was shared by 22% of all genes, while terms such as 'response to oxidative stress' (6.25%, P ¼ 0.001), 'response to pest/pathogen/parasite' (12.5%, P ¼ 0.006) and 'superoxide metabolism' (3.1%, P ¼ 0.02) were significant only at the unadjusted level. These terms were usually confirmed to be over-represented also by the analysis with MAPPFinder, even if extended to a wider set of gene ontology terms (see Supplementary  Table 3 ). Indeed, several terms are related through the hierarchical relationship among them (for example 'superoxide metabolism', that was found over-represented by FatiGO, is not in the list selected by MAPPFinder, although there is its parent term 'oxygen and reactive oxygen species metabolism'). Among downregulated genes, 'cell cycle' was the most represented term (at 52.4%) and this had a highly significant adjusted P-value (Po0.0001), while 'DNA metabolism' and 'cytokinesis' showed the same level of significance but lower percentage representation (32 and 11%, respectively). Other terms significant only at the unadjusted P-value were: 'nucleobase biosynthesis', 'nucleobase metabolism', 'defence response', 'RNA metabolism', 'amino-acid metabolism', 'nucleotide metabolism', 'cell surface receptor-linked signal transport', 'ion transport' and 'carboxylic acid metabolism'. As observed for the upregulated set, these terms were among those found significantly over-represented also with MAPPFinder (see Supplementary Table 4) . Furthermore, several terms were specifically related to DNA replication, mitosis and cell cycle regulation, suggesting an inhibition in the cell cycle progression.
In Supplementary Table 1 , we list the genes known to be associated with the activation of the IFN signalling pathway, whose expression was found upregulated after treatment in the cell lines (43 out of 127 genes, which represents 34% of all the upregulated genes). Among these, the interferon gamma (IFNg) receptor 1 (IFNGR1) and the Signal Transducer and Activator of Transcription 1 (STAT1) were upregulated only in PaCa44-and CFPAC1-treated cells.
Western blot analysis of STAT1, p21
WAF1 and p16
INK4
To investigate further the involvement of the IFN pathway in the response to 5-aza-CdR treatment, we focused our attention on STAT1 and p21 WAF1 (Karpf et al., 1999; Liang et al., 2002) . Western blot analysis showed that the expression of STAT1 protein and its phosphorylated form ( Figure 5 ) paralleled the increased expression of STAT1 mRNA observed by microarray analysis after treatment with 5-aza-CdR in PaCa44 and CFPAC1 cell lines, while in MiaPaca2 STAT1 was expressed at a very low level under all conditions.
We also analysed the expression of p21 WAF1 by Western blot, as its promoter region contain the palindromic sequences recognized by STAT1 (Chin et al., 1996) . In addition, it has been shown that there is a correlation between hypermethylation of the STATbinding site (sis-inducible element (SIE)-1) in the p21 WAF1 promoter region and decreased protein expression (Chen et al., 2000) . The results shown in Figures 5 and 6 are concordant with this hypothesis, confirming the hypermethylation of SIE-1 in all three cell lines, which is reverted by 5-aza-CdR. However, we observed an increased expression of p21 WAF1 only in PaCa44 and CFPAC1 cells, where STAT1 was expressed and upregulated after treatment. On the other hand, the lack of STAT1 expression in MiaPaCa2 is associated with no change in p21 WAF1 mRNA and protein level. Inactivation of the p16 INK4 gene is a frequent event in pancreatic cancer, due to either mutation and/or deletion of the gene locus, or methylation of its promoter region responsible for expression silencing (Herman et al., 1995) . As p16 INK4 was not represented on our cDNA microarray and its reactivation has been associated with the inhibition of tumour growth induced in different cell lines by 5-aza-CdR treatment (Bender et al., 1998; Suh et al., 2000) , we investigated its expression using Western blot analysis. The status of p16 INK4 in different pancreatic cancer cell lines has already been assayed showing promoter hypermethylation in PaCa44 and CFPAC1, while MiaPaCa2 has p16 INK4 homozygous deletion . As expected, we found upregulated protein expression only in PaCa44 and CFPAC1, supporting the successful demethylation of the p16 INK4 promoter ( Figure 5 ) as well as its possible involvement in the efficacy of the 5-azaCdR treatment on cell proliferation.
Other genes differentially expressed involved in cell cycle progression
We examined the expression levels of CDC2, cyclin B1, PCNA and 14-3-3s by RT-PCR to verify their behaviour after treatment with 5-aza-CdR. As reported in Figure 3b , the expression of CDC2 and cyclin B1 was reduced by the treatment in both PaCa44 and CFPAC1 cells, while 14-3-3s and PCNA were downregulated only in CFPAC1. Expression of the 14-3-3s gene in MiaPaCa2 cells is known to be silenced by methylation and its re-expression after 5-aza-CdR treatment has already been described (Iacobuzio-Donahue et al., 2003) .
Methylation status of genes found re-expressed after 5-aza-CdR
Among the genes induced after 5-aza-CdR treatment, we selected two genes known to be frequently methylated, 14-3-3s and RARRES1. The former was only upregulated in MiaPaCa2 cells, while the latter was upregulated in both PaCa44 and CFPAC1 cells. The results are shown in Figure 7 . The MSP analysis revealed that only MiaPaCa2 was originally fully methylated in the CpG island within the first 14-3-3s exon, and 5-aza-CdR treatment partially reverted that status. This is in agreement with both our RT-PCR results and reported data (Iacobuzio-Donahue et al., 2003) . RARRES1 showed a partial methylation in its promoter region in all three cell lines, although to a different degree. However, the treatment affected mostly MiaPaCa2 and PaCa44, as evident by the decreased intensity of the signal for the methylated fragment in these two cell lines.
IFN pathway-related genes
The results obtained using quantitative RT-PCR confirmed the differences observed using microarray analysis for seven genes belonging to the IFN pathways (Table 2 ). In particular, all seven genes were shown to be differentially expressed in treated PaCa44 and CFPAC1, as expected. However, statistically significant differences were also identified in MiaPaCa2 cells for the gadd45A, ISG20 and ubiquitin D genes. For the first two, the fold inductions observed in MiaPaCa2 were always lower than those in PaCa44 and CFPAC1 and close to the threshold level used as cutoff in the microarray analysis, Figure 5 Western blot analysis of three gene products (Stat1, p21 and p16) found differentially expressed 6 days after treatment with 5-aza-CdR Figure 6 Methylation status of the SIE-1 element in p21 WAF1 promoter region by genomic DNA digestion with methyl-sensitive restriction enzyme HpaII, followed by a PCR that spans the SIE-1 element. Amplification of the PCR product indicates the presence of methylcytosine in the SIE-1 CpG site, which block the enzyme cleavage. 5-aza-CdR treatment induces the methyl group removal so that HpaII disrupts the target template for the PCR reaction. cKit was used as positive control Figure 7 MSP analysis of 14-3-3s and RARRES1 genes. The treated samples (T) were analysed after 6 days from the 5-aza-CdR exposure and compared to the untreated samples (C). The lanes U and M represent the amplification products from unmethylated and methylated templates, respectively Growth delay of human pancreatic cancer cells E Missiaglia et al while ubiquitin D was expressed at a very low level (more than 1 million times less expressed) compared to b-actin.
Combined treatment with 5-aza-CdR and other anticancer drugs
To verify the ability of 5-aza-CdR to sensitize the cell lines to further treatment, we combined this agent with other drugs, some of which are frequently used for pancreatic cancer chemotherapy. These included gemcitabine, 5-fluorouracil (5-FU), cisplatin, IFNg and tumour necrosis factor alpha (TNFa). As expected from the molecular response observed, the combination of 5-aza-CdR and IFNg (100 U/ml) produced an additive effect, with percentages of cells of 39 and 37% in PaCa44 and CFPAC1 cell lines, respectively, compared to untreated controls, which were significantly lower than 50% (P ¼ 0.003) and 55% (P ¼ 0.05) observed with 5-aza-CdR alone, or 66% (P ¼ 0.0003) and 63% (P ¼ 0.03) with IFNg alone. Conversely, the value for MiaPaCa2 cells was only 69%, which is similar to the effect of IFNg alone (Figure 8 ). Positive effects were also observed for a combination of 5-aza-CdR with cisplatin and gemcitabine. In particular, we observed a significant inhibition effect with cisplatin associated with 5-azaCdR in PaCa44 (38% compared to 50% obtained with 5-aza-CdR alone; P ¼ 0.04) and CFPAC1 (22% compared to the 36% when Cisplatin was used alone; P ¼ 0.0002), while Gemcitabine was more effective in In the table the median number of cycles normalized and scaled for controls and treated samples is reported. The differences were evaluated using Mann-Whitney test 
Discussion
Previous studies have proven convincingly the role of aberrant methylation in the initiation and progression of several tumour types, including pancreatic adenocarcinoma. In fact, methylation of CpG islands or sites is frequently associated with silencing of tumour-suppressor genes that may represent a selective advantage in terms of growth and survival for the affected cells. Pancreatic adenocarcinoma is characterized clinically by a wide resistance to all current chemotherapy treatments. The aim of this study was to assess the efficacy of 5-aza-CdR treatment in inhibiting cell growth or inducing sensitization to further drugs in pancreatic cancer cell models. Several clinical trials of 5-aza-CdR administration conducted in diverse tumour types have shown various degrees of efficacy, particularly in solid tumours (for reviews, see Santini et al., 2001; Aparicio and Weber, 2002) . On the other hand, a recent study has suggested that 5-aza-CdR treatment may stimulate invasion in some pancreatic cancer cell lines by reactivation of invasion-promoting genes (Sato et al., 2003b) . In the present study, we sought to identify the molecular mechanisms behind differential effects in pancreatic cancer by analysing the alteration in gene expression profile induced by 5-aza-CdR treatment in cell models.
Analysis of cell growth and cell cycle distribution revealed differential responses of individual cell lines to treatment with this drug. We selected the relatively unresponsive MiaPaCa2 cell line, as well as the PaCa44 and CFPAC1 cell lines, which show strong inhibition of cell proliferation associated with arrest or delay in S or G2/M phases. Low rates of induction of apoptosis confirmed that 5-aza-CdR treatment produces a predominantly cytostatic effect in these pancreatic cancer cell lines, as observed for other cancer cell lines (Davidson et al., 1992; Caraglia et al., 1994; Karpf et al., 1999; Sato et al., 2003a) .
We confirmed the effect of 5-aza-CdR on methylation status in all the treated cell lines. The level of DNMT1, assayed by RT-PCR, was downregulated in response to the treatment only in PaCa44 and CFPAC1 cell lines (confirmed by microarray analysis). Among the other methyltransferases, DNMT3b showed a different profile of splicing variants in the various cell lines. These variants may have alternative catalytic activity and different target specificity (Robertson et al., 1999 Saito et al., 2002) and may be responsible for a different DNA methylation pattern (Beaulieu et al., 2002) . Recently, Rhee et al. (2002) have demonstrated that DNMT3b play an essential role in the maintenance of DNA methylation and gene silencing in cooperation with DNMT1. In particular, DNMT3b3 variants allow de novo methylation of various target sequences (Weisenberger et al., 2004) and their continued expression in MiaPaCa2 cells after exposure to 5-aza-CdR may explain the different effect on gene expression profile in this cell line. In fact, the analysis of a few specific methylation sites gave evidence for their frequent hypermethylation particularly in the MiaPaCa2 cell line, which confirms the results of other studies where this cell line was among those with a higher number of hypermethylated genes (Ueki et al., 2000; Sato et al., 2003a, c) . Thus, we may speculate that the variability in the methylation status observed among the three cell lines under study could partially explain the difference in the response to 5-aza-CdR treatment.
The tumour suppressor genes p16 INK4 and p53, which are critically involved in pancreatic cancer tumorigenesis, are also implicated in the response to 5-aza-CdR treatment (Bender et al., 1998; Suh et al., 2000; Nieto et al., 2004; Zhu et al., 2004) . The analysis of the expression of p16 protein confirmed its upregulation after the treatment in both PaCa44 and CFPAC1. However, the S and G2/M delay observed, together with results of previous studies that showed a p16 INK4 -independent growth inhibition of tumour cells induced by 5-aza-CdR (Bender et al., 1998) , suggests that its effect is not limited to the re-expression of p16
INK4 . The analysis of global gene expression profiles further corroborates the observation of a different biological behaviour for the MiaPaCa2 cell line in comparison to the other two. Starting from the similarity between the PaCa44 and CFPAC1 gene expression profiles, we Figure 9 Percentage of cells observed at 72 h after the single and combined treatments with 5-aza-CdR compared to control observed at 72 h after the single and combined treatments with 5-aza-CdR (2 mM) and TNFa (3 ng/ml), gemcitabine (PaCa44: 64 mM, CFPAC1: 15 nM, MiaPaCa2: 0.25 mM), cisplatin (PaCa44: 20 mM, CFPAC1: 10 mM, MiaPaCa2: 4,5 mM) and 5-fluorouracil (PaCa44: 32 mM, CFPAC1: 64 mM, MiaPaCa2: 16 mM). The comparisons made between the strongest single treatment against the combined treatment showed that the combination of 5-aza-CdR with Cisplatin reduced significantly the percentage of cell compared to PaCa44 treated with only 5-aza-CdR (P ¼ 0.04) and CFPAC1 treated only with Cisplatin (P ¼ 0.0002). Equally, the combined treatment with Gemcitabine and 5-aza-CdR in PaCa44 was stronger than the treatment with Gemcitabine alone (P ¼ 0.
002). (n) Significantly inhibited by combined treatment
Growth delay of human pancreatic cancer cells E Missiaglia et al superimposed their differentially expressed genes to identify common pathways involved in the biological response induced by 5-aza-CdR treatment. Gene ontology analysis of common downregulated genes demonstrated that 'cell cycle', 'mitosis', 'DNA metabolism' and 'cytokinesis' terms were over-represented, in agreement with the delay in cell cycle progression observed. Conversely, upregulated genes showed over-represented terms such as 'defence response', 'response to pest/ pathogen/parasite' and 'superoxide metabolism'. Interestingly, several upregulated genes were found to belong to the IFN pathway and IFN cytokines may modulate immune responses and exert antiproliferative effects in some cell types by inhibiting DNA replication and protein synthesis (Clemens and McNurlan, 1985) . This may explain the frequent occurrence of terms such as 'DNA metabolism', 'RNA metabolism', 'amino-acid metabolism', 'nucleobase biosynthesis' and 'nucleobase metabolism' for our downregulated genes.
Previous studies on the effects of 5-aza-CdR on gene expression profile in colon and bladder cancer cell lines have already described the induction of IFN-responsive genes as the major cellular response to this treatment, suggesting their involvement in the observed growth inhibition (Karpf et al., 1999; Liang et al., 2002) . Furthermore, inhibition of DNMT1 activity, using a conditional mutation in a mouse model, has shown a similar response at the gene expression profile level, indicating that the activation of this pathway is associated with the specific effect of 5-aza-CdR on DNMT1 activity rather than a secondary cytotoxic outcome (Jackson-Grusby et al., 2001 ). In addition, in a recent study, the epigenetic silencing of multiple genes that belong to the IFN pathway has been shown to be involved in cellular immortalization, which was then reverted by treatment with 5-aza-CdR, suggesting that this alteration may be associated with an early event in tumorigenesis (Kulaeva et al., 2003) .
Our study produced analogous results, emphasising the role of IFN pathway activation also in the pancreatic cancer cell model. Specifically, the treatment increased the expression of IFNGR1 and STAT1 genes, as well as others known to be induced by IFNs, such as Mx2, G1P2, ISG20 and UBD. IFNGR1 is part of a complex that mediates the activation of the transcription factor STAT1a by tyrosine phosphorylation on Tyr701 after its interaction with the IFNg cytokine (Shuai et al., 1993) . The STAT1 protein is a transcription factor (for a review, see Ramana et al., 2000) that mediates the antiproliferative response to interferon stimulation (Bromberg et al., 1996) . This negative effect on cell proliferation is coupled particularly with p21 WAF1 upregulation (Chin et al., 1996; Hobeika et al., 1998; Kominsky et al., 1998; Chen et al., 2000) , but downregulation of CCNA2 (cyclin A) (Sibinga et al., 1999) , or cyclin D and Cdc25A (Tiefenbrun et al., 1996) , has also been described.
In our study, we observed hypermethylation of the SIE-1 site in the p21 WAF promoter region in all three cell lines, which was partially reverted by 5-aza-CdR treatment and coupled with increased p21 WAF expression at both the transcriptional and protein level only in PaCa44 and CFPAC1 cells, where it was associated with STAT1 expression. Although the p21 WAF1 protein is frequently responsible for G1 arrest, numerous pieces of evidence suggest a role also in S/G2 transition. p21 WAF1 is thought to induce G2 arrest by interacting with the Cdc2-cyclinB1 complex together with PCNA, and thus prevents incorporation of Cdc25C that can activate the Cdc2-cyclinB1 complex by dephosphorylation (Ando et al., 2001) . However, inhibition of S/G2 transition may also involve interaction of p21 WAF1 with the Cdc2-cyclinA complex (Dulic et al., 1998) . Furthermore, p21
WAF1 can inhibit the interaction between PCNA and the DNA polymerase delta, which is essential for DNA replication and repair, and consequently inhibit DNA synthesis (Rousseau et al., 1999; Lu et al., 2002) . Downregulation of DNMT1, which competes with p21 WAF1 for the same binding site on PCNA (Chuang et al., 1997; Fang and Lu, 2002) , may further enhance the inhibitory effect of 21 WAF1 on both DNA synthesis and cell growth.
Gadd45A, that includes three CpG-rich regions among its exons and introns (data not shown), is another key gene found upregulated in 5-aza-CdRtreated cells, whose expression can be increased by IFNg treatment (Brysk et al., 1995) as well as by p53 activity (Carrier et al., 1994) . It has been associated with cell growth suppression and G2/M cell cycle arrest by altering cyclin B1 nuclear localization and inhibiting Cdc2 activity in a p53-dependent manner (Jin et al., 2002) . However, Hirose et al. (2003) have observed induction of G2/M arrest caused by Gadd45A upregulation after chromatin structure reorganization by treatment with histone deacetylase inhibitors without the need for functioning p53.
Hence, we speculate that upregulation of p21 WAF1 and Gadd45A may be responsible for the cell cycle arrest or delay observed after treatment with 5-aza-CdR by altering the formation and activation of Cdc2-CyclinB1 complex. Moreover, the p53 mutations present in all cell lines under study ) may inhibit apoptotic pathways, explaining the low apoptotic rate induced by the treatment. We may also speculate that downregulation of several genes associated with the S and G2/M phases of the cell cycle, found with the microarray analysis, is due to this cell cycle delay rather than a direct effect of the drug treatment. In fact, we may expect that the differential expression observed for several genes may be independent of their own methylation status.
In agreement with a recent report (Sato et al., 2003b) , the gene expression profile analysis also demonstrated that treatment with 5-aza-CdR induces the expression of several genes associated with tumour invasion and metastasis, such as CTSB, DAF, MMP15, t-PA and u-PAR, as well as the apoptotic suppressor BIRC3. However, we found upregulation of other genes that may inhibit matrix degradation (TIMP1 and PAI-1) or stimulate the immune response (HLA-E, LY6E or SSX4). Further studies are needed in order to evaluate if the balance between these positive and negative effects results in an enhancement of invasion and metastasis in vivo.
Interestingly, the treatment induced or inhibited the expression of several genes found, respectively, down-or upregulated in primary pancreatic cancer in other studies (see Supplementary Tables 3 and 4) . In particular, among the induced genes, DUSP6 has been suggested to exert tumour-suppressive effects in vitro in pancreatic cancer by inhibiting phosphorylation of ERK (Furukawa et al., 2003) . Among the downregulated set, we also found the gene CAD, described as upregulated in intraductal papillary mucinous neoplasms of the pancreas (Sato et al., 2004) , whose activity seem to be directly regulated by ERK2. This gene catalyses the initial, rate-limiting step in the de novo synthesis of pyrimidine nucleotides (Jones, 1980) and its inhibition may potentially explain the downregulation of several genes related to nucleotide synthesis (such as TK1, TYMS, GMPS, DTYMK) observed after treatment with 5-aza-CdR.
Finally, we combined 5-aza-CdR treatment with other chemotherapy agents in order to verify if the induction of genome-wide demethylation led to chemosensitization. We observed that IFNg treatment gave an additive effect in combination with methyltransferase inhibitor where its pathway was upregulated, confirming that its activation represents an important mechanism for the biological alterations induced by 5-aza-CdR treatment. Similar interactions have been described between 5-azaCdR and IFN-a in haematological tumour cell lines (Dore and Momparler, 1992; Reid et al., 1992) . Combination of 5-aza-CdR treatment with gemcitabine or cisplatin also showed more marked inhibitory effects than the single treatments alone. Hence, combined treatment with 5-aza-CdR and drugs commonly used for pancreatic cancer chemotherapy could improve their effect in inhibiting tumour growth.
Materials and methods
Cell lines
MiaPaca2, PaCa44 (both originating from primary tumours) and CFPAC1 (originating from liver metastasis) adenocarcinoma cells were cultured at 371C in 5% CO 2 by using RPMI 1640 medium (GIBCO) supplemented with 10% foetal bovine serum (FCS) (GIBCO), 1% gentamicin (Gentalyn 80 -Schering-Plough Spa) and 1% L-glutamine (GIBCO). The medium was renewed every 2 or 3 days. When the cells became confluent, they were removed from the bottom of the culture flasks by 0.5% porcine trypsin with 0.2% EDTA in Dulbecco's phosphate-buffered saline (PBS).
Cell growth assay
Cells (10 4 /well) were plated in 48-well culture plates (Nunc Inc.) and treated after 24 h with a single dose of 2 Â 10 À6 M 5-Aza-CdR (Sigma) that was left in the medium for 24 h and then removed when a new drug-free medium was added to the plates. The cell mass was assayed by crystal violet staining at 2-day intervals up to 10 days. Control cells were analysed under the same conditions until they reached confluence.
Cell cycle profile
Cell DNA content was measured in triplicate at 3-day intervals up to 9 days under the same conditions. Cells were plated at 2 Â 10 5 /well in six-well culture plates (Orange Scientific), and washed and treated with hypotonic fluorochrome solution at appropriate intervals (0.1% sodium citrate, 0.1% Triton X-100, 20 mg/ml RNase and 50 mg/ml propidium iodide) (Sigma). The cells were incubated for 30 min at room temperature in the dark before analysis. The fluorescence intensity of propidium iodide was measured by a FACSCAN flow cytometry (Becton Dickinson). Doublets were discriminated by using a peak fluorescence gate. Cell cycle distribution was determined by Modfit software (Home Verity).
Apoptosis
Apoptosis was assessed by detection of histone-associated DNA fragments 6 days after 5-aza-CdR treatment. Cells were analysed using the Cell-Death Detection ELISA Plus assay (Roche Molecular Biochemicals). The assay is based on a quantitative sandwich-enzyme-immunoassay principle using anti-histone-biotin and anti-DNA-peroxidase (POD) monoclonal antibodies. POD was determined photometrically (A 405 nm -A 492 nm ) with 2,2 0 azino-bis(3-ethylbenzthiazoline)-6-sulfonic acid (ABTS) as substrate. This allows the determination of the apoptotic enrichment of nucleosomes in the cytoplasmic fraction of cell lysates.
Combined treatment
Cells (4 Â 10 3 /well) were plated in 96-well culture plates (Nunc Inc.) and treated after 24 h with 2 mM 5-Aza-CdR. A second treatment was added using the following drugs and conditions: 100 U/ml of IFNg (Sigma) maintained for 72 h, 3 ng/ml of TNFa (Sigma) maintained for 72 h; cisplatin (Pharmacia and Upjohn S.p.A.), gemcitabine (Eli Lilly Italia S.p.A.) and 5-FU (Teva Pharma Italia S.r.l.) were added at approximately IC 50 concentrations (see Figures 8 and 9 for details) after 24 h and maintained for the last 48 h. The level of growth inhibition was assessed at 72 h as described above. In order to provide evidence for the possible positive effect of drug association, we tested the difference between the strongest single treatment against the combined treatment using the Welch two-sample ttest, considering a P-valueo0.05 as significant.
5mC content in genomic DNA
Genomic DNA was obtained from treated cell lines at the third and sixth days by digestion with proteinase-K (Sigma) and RNase-A (Promega), followed by phenol-chloroform extraction. In all, 1 mg of DNA from each sample was then digested with McrBC enzyme (New England Biolabs), which cleaves DNA-containing methylcytosine on one or both strands, and resolved on a 1.5% agarose gel.
Methylation status of the SIE-1 element in p21 WAF1 promoter region
We tested the presence of methylcytosine in the CpG site inside the sis-inducible element (SIE)-1 (a STAT-responsive element represented by the sequence 5 0 -CTTCCCGGAAG-3 0 ) at nt À692 in the promoter region of p21 WAF1 (Chen et al., 2000) using PCR associated with the methylation-sensitive restriction enzyme HpaII. In all, 2 mg of genomic DNA was digested overnight with 40 U of HpaII (New England Biolabs, Beverly, MA, USA) at 371C. Then, 1 ml of digested product was PCR amplified using the following primers: p21F 5 0 -GAGTG- 0 . Cycling conditions were 941C for 3 min, followed by 35 cycles of 941C for 20 s, 551C for 25 s and 721C for 20 s. PCR products were subjected to electrophoresis on 2% agarose gel and stained with ethidium bromide.
Methylation-specific PCR (MSP)
In all, 2 mg of DNA was BamHI digested and treated with sodium bisulfite as described (www.mcdb.ucla.edu/Research/ Jacobsen/BisulfiteGenomicSequencing.html), with slight modification consisting in the addition of urea to the bisulphite reaction (Paulin et al., 1998) . Then, 1 ml of bisulfite-treated DNA was the template for PCR using primers and the condition previously described for 14-3-3s (Ferguson et al., 2000) and RARRES1 (Youssef et al., 2004) genes.
5-Aza-CdR treatments for gene expression profiles
Cells were exposed to 2 Â 10 À6 M 5-Aza-CdR 24 h after passage in complete culture medium. At 24 h after drug addition, the culture medium was replaced with drug-free medium. Each cell line was treated in triplicate, in parallel with a triplicate control. The culture density was set to reach 80% of confluence at 6 days after treatment, as well as in the control dishes.
RNA extraction
Total RNA was extracted using TRIZOL (Gibco BRL, Life Technologies Inc., Frederick, MA, USA) according to the manufacturer's protocol. RNA was resuspended in DEPCtreated water and quality verified by agarose gel electrophoresis stained by SYBRGold dye (Molecular Probes).
cDNA microarray
The 10K cDNA microarrays used in this study were obtained through the Cancer Research UK/Ludwig/Wellcome Trust consortium at the Sanger Centre, Cambridge, UK. The 10K slides contained 10 752 elements comprising 9464 human I.M.A.G.E clones and 468 chromosome 22 gene-specific PCR products, together with positive and negative controls. The spotting patterns and the complete annotated list of cDNAs are available at the following web site: http://www.sanger.ac.uk/Projects/Microarrays/informatics/ hver1.2.1.shtml.
Experimental design, cDNA preparation, hybridisation and scanning
Each treated and control sample was cultured in triplicate for 6 days and then labelled by direct incorporation of Cy5-dCTP fluorochrome (Amersham Pharmacia Biotech). Each of the treated and control samples was cohybridized with the appropriate reference sample, which consisted of the pool of the total RNA isolated from the three control dishes of the same cell line labelled with Cy3-dCTP. This design was followed for each cell line. The details of the hybridisation and washing protocols are available (http://www.cgal.icnet.uk/ exprotocols/protocols.html). After washing, fluorescence intensities were scanned by dual-laser Affymetrix 428 Scanner (Affymetrix, High Wycombe, UK Ltd).
Image and data analysis
The scanned images were analysed using the ImaGene v4.2t software (BioDiscovery, Los Angeles, CA, USA). Quality measures were used to identify negative (background4signal), poor ((mean signalÀmean background)/SD signal 40.45) and empty spots (signal/SD signal 42.3). Only the spots that were not flagged and above background (total signal 41.4 Â background in both channels) were retained. The mean signal subtracted for the background was used in the subsequent analysis. We used the robust, locally linear lowess function to perform a within-print tip group normalization followed by a scale normalization (Yang et al., 2002) using marrayNorm package in R (Ihaka and Gentleman, 1996) . The log-square ratios of the normalized values from treated and pooled samples were compared to the ratios from control samples and pool using SAM (Tusher et al., 2001) . Missing data were integrated by the k-nearest neighbour algorithm only when a single value per gene was missing. The input criteria were based on fold change greater than 1.5 between treated and control cells and a delta value expected to originate a data set with less than 2% of false positives (using the median of the number of falsely called genes) in order to reduce the error due to multiple testing. The overall correlation between samples was obtained using the 'cor' function and Spearman correlation as distance metric in the R program, while the statistical significance of the differences between treated samples were investigated by the Mann-Whitney test. A cluster of samples was generated using the 'cluster' and 'mva' packages applying an agglomerative method, averagelinkage and Euclidian distance on a set of genes for which a value was available in each sample.
Gene ontology analysis
In order to identify biological processes significantly involved in the drug effect, genes considered differentially expressed between treated and control cell lines were processed through two programs (FatiGO and MAPPFinder) in which the gene products are annotated to the gene ontologies by diverse association tables (GOAnnotation@EBI and LocusLink/ loc2go). In particular, the FatiGO Data mining program (http://fatigo.bioinfo.cnio.es/) (Al-Shahrour et al., 2004) , was interrogated using the Ensembl gene identifier (http://www.ensembl.org/), comparing the fifth level terms of genes up-or downregulated against 1000 randomly selected genes from our microarray after removing the genes under analysis. In addition, the Gene Ontology terms were obtained using LocusLink ID to query the MAPPFinder2 program (http:// www.GenMAPP.org) (Doniger et al., 2003) , that also expands each term to the parent terms using the GO DAG structure file for each individual ontology. Only the terms with an absolute z score over 2 and at least 5, but less than 28, genes meeting the criteria (for upregulated and belonging to the specific term) or less than 50 (for downregulated and belonging to the specific term), as well as a significant P-value (calculated by a non parametric bootstrapping approach), have been reported in two separate tables (Supplementary Tables 3 and 4) .
Western blot analysis
The proteins were extracted using TRIZOL (Gibco BRL) according to the manufacturer's protocol and dissolved in 1% SDS. Protein concentration was measured using Bio-Rad protein assay (Bio-Rad) and BSA (Sigma) to generate a standard curve. In all, 20 mg of proteins was fractionated by electrophoresis in 8 or 15% SDS-polyacrylamide 1 mm gels and electroblotted onto nitrocellulose membranes. Blocking buffers were either 5% of non-fat dry milk or 1.5% of BSA plus 0.05% Tween20 in PBS. The primary antibodies were all from Upstate (Lake Placid, NY, USA) and included: anti-STAT1-CT (rabbit polyclonal IgG), anti-P-STAT1 (phospho Ser 727) (rabbit polyclonal IgG), anti-p21waf1/cip1 (mouse IgG derived from two clones) and anti-human p16 INK4a (16 kDa) (mouse monoclonal IgGk). Secondary antibodies (anti-rabbit anti-mouse) conjugated with HRP were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The fragments were detected using ECL kit (Amersham) and BioMax films (Kodak).
RT-PCR
cDNAs were synthesized from 1 mg of total RNA using an oligo dT primer and the Superscript II reverse transcription kit (GibcoBRL) according to the manufacturer's protocol. In all, 1 ml of the cDNA was used for each PCR in a 20 ml reaction volume containing 200 mM dNTPs, 1 mM sense and antisense primers, 1.25 mM MgCl 2 , 2 ml of 10 Â PCR buffer and 0.5 U of Taq polymerase (Roche). PCR conditions and primers used are reported in Table 3 . b-Actin was used as the endogenous control. The PCR products were analysed by electrophoresis on a 2% agarose gel, followed by staining with ethidium bromide.
Quantitative real-time RT-PCR
Among the induced genes, seven belonging to the IFN pathway were chosen to be validated by quantitative RT-PCR, using Assays-on-Demand t Gene Expression reagents (Applied Biosystems). These were CCNA2 (Hs00153138_m1), GADD45A (Hs00169255_m1), IFNGR1 (Hs00166223_m1), UBD (Hs00197374_m1), Mx2 (Hs00159418 m1), G1P2 (Hs00192713_m1) and ISG20 (Hs00158122_m1). cDNAs were prepared from the three independent RNA samples from control and treated cells used for the microarray experiments. Quantitative RT-PCR was performed in 25 ml containing 1 ml of five times dilution of the reverse transcription product according to the manufacturer's protocol using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems). Each sample reaction was repeated twice and the b-actin transcript level was used as a reference control.
In order to make all the data comparable, the number of cycles was normalized by subtracting the related mean number of cycles for the b-actin (Hs99999903_m1), and scaled subtracting the lowest median among our six experimental conditions. The statistical significance of the differences between controls and treated samples was investigated by the Mann-Whitney test. All the analysis was performed using the R program.
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